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Acute myeloid leukemia (AML) is a heterogeneous
disease caused by mutations in transcriptional regu-
lator genes, but how different mutant regulators
shape the chromatin landscape is unclear. Here, we
compared the transcriptional networks of two types
of AML with chromosomal translocations of the
RUNX1 locus that fuse the RUNX1 DNA-binding
domain to different regulators, the t(8;21) expressing
RUNX1-ETO and the t(3;21) expressing RUNX1-EVI1.
Despite containing the same DNA-binding domain,
the two fusion proteins display distinct binding pat-
terns, show differences in gene expression and chro-
matin landscape, and are dependent on different
transcription factors. RUNX1-EVI1 directs a stem
cell-like transcriptional network reliant on GATA2,
whereas that of RUNX1-ETO-expressing cells is
more mature and depends on RUNX1. However,
both types of AML are dependent on the continuous
expression of the fusion proteins. Our data provide a
molecular explanation for the differences in clinical
prognosis for these types of AML.
INTRODUCTION
Acute myeloid leukemia (AML) is the most common acute leu-
kemia in adults. Despite improvements in supportive care, out-
come typically remains poor for AML patients older than 60 years
who are unfit for intensive chemotherapy (Dennis et al., 2015).
AML is highly heterogeneous and has been subdivided accor-
ding to different categories of disease-causing mutations asso-
ciated with different therapeutic responses. Subclasses are pri-
marily defined by mutations in transcription factors, epigenetic
regulators, and signaling molecules that affect cell growth and
transcription factor activity (Cancer Genome Atlas Research
Network, 2013; Papaemmanuil et al., 2016). Consequently,
myeloid differentiation is impaired at different developmental
stages, and different sets of genes are activated or repressed1654 Cell Reports 19, 1654–1668, May 23, 2017 ª 2017 The Author(s
This is an open access article under the CC BY license (http://creativein distinct subsets of AML. Currently, the molecular details of
how specific mutant transcriptional regulator proteins affect
different sets of genes, and how such deregulated transcrip-
tional networks impact myeloid differentiation, are unknown.
Mutations involving the hematopoietic master regulator
RUNX1 are among the most commonly found abnormalities in
AML. RUNX1 is the DNA-binding component of core binding fac-
tor (CBF), binding as a dimer with CBFb, which is encoded by
another recurrently rearranged gene in AML. The most common
category of RUNX1 rearrangement is the product of the t(8;21)
chromosomal translocation, RUNX1-ETO, which comprises the
RUNX1 DNA-binding domain linked to the almost complete
ETO protein (also known as RUNX1T1), which functions as a
repressor by recruiting histone deacetylases (Bae et al., 1993;
Erickson et al., 1992) (Figure 1A). The t(8;21) translocation in-
volves 12% of newly diagnosed younger patients with AML
(Grimwade et al., 2010). RUNX1-ETO leads to a block in myeloid
differentiation (Cabezas-Wallscheid et al., 2013; Okuda et al.,
1998; Regha et al., 2015), and its expression is required for
leukemic propagation (Dunne et al., 2006; Heidenreich et al.,
2003; Martinez et al., 2004; Ptasinska et al., 2012).
The product of anotherRUNX1 translocation, t(3;21)(q26;q22),
is RUNX1-EVI1, whereby the RUNT domain is fused to the entire
EVI1 gene (Figure 1A) (Mitani et al., 1994; Nucifora et al., 1994).
EVI1 (also known asMECOM or PRDM3) encodes a dual domain
zinc-finger transcription factor with direct DNA-binding activity
together with a histonemethyl transferase (SET) domain (Morish-
ita et al., 1995) (Figure 1A) and is an essential regulator of self-
renewal in hematopoietic stem cells (Goyama et al., 2008). The
t(3;21) translocation is rarely found in patients with de novo
AML (Lugthart et al., 2010) and is more commonly found in those
with therapy-related myelodysplastic syndrome (MDS)/AML
(Rubin et al., 1990) or as a secondary event in the transformation
of chronic myelogenous leukemia (CML) from chronic phase to
blast crisis (Nukina et al., 2014).
Although RUNX1-ETO and RUNX1-EVI1 carry the same DNA-
binding domain and bind to the same motifs in vitro (Meyers
et al., 1993; Tanaka et al., 1995), the two classes of AML have
distinct clinical characteristics. The t(8;21) translocation gener-
ally has a better clinical outcome than the t(3;21) translocation
(Byrd et al., 2002; Grimwade et al., 2010; Slovak et al., 2000),).
commons.org/licenses/by/4.0/).
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Figure 1. t(3;21) and t(8;21) Are Epigenetically Distinct Types of AML
(A) Structure of RUNX1, RUNX1-ETO, and RUNX1-EVI1 with their interacting partners. AA, amino acids; RHD, Runt homology domain; TA, transactivation
domain; NHR, nervy homology region; SET, Su(var)3-9 and ‘‘Enhancer of zeste’’; ZF, zinc finger domain; RD, proline-rich repressive domain; CBP, CREB-binding
protein; HDAC, histone deacetylase; CtBP, C-terminal-binding protein; N-CoR, nuclear receptor co-repressor.
(B) UCSC genome browser screenshot of DNase-seq and corresponding RNA-seq in two patients with t(3;21) AML, two patients with t(8;21) AML, t(3;21) cell line,
and normal CD34+ PBSCs at theMEIS1 locus. An enhancer (Xiang et al., 2014) denoted at +140 kb is accessible in t(3;21) AML and normal CD34+ PBSCs, but not
in t(8;21) AML.
(C) Clustering based on the strength of correlation between samples of DNase-seq data from cells of two patients with t(3;21), two patients with t(8;21), two
independent CD34+ PBSCs, and the t(3;21) SKH-1 cell line.
(D) Correlation clustering of RNA-seq data (as in C) from two t(3;21) patients and the SKH-1 cell line with two t(8;21) patients and two normal CD34+ PBSCs.
(E) DNase-seq profiles spanning 4-kb windows for t(3;21) patient 2, t(8;21) patient 1, and SKH-1 cells. Peaks are ranked from top to bottom in order of increasing
relative DNA sequence tag count for peaks identified in t(8;21) patient 1 relative to t(3;21) patient 2. The heatmaps to the right depict the relative expression of
genes nearest to each DHS calculated as the ratio of FPKM values for t(3;21) patient 2 (P2) divided by values for t(8;21) patient 1 (P1) or patient 2 (P2).
(F) Venn diagram showing the overlap of DNase-seq peaks between t(3;21) patients (both patients combined) and t(8;21) patients (both patients combined).
(G) De novo motif discovery in distal DHSs unique to t(3;21) as compared to t(8;21) patients and distal DHSs unique to t(8;21) compared to t(3;21) patients (as
shown in F).
See also Figure S1.
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and the 5-year event-free survival for t(3;21) patients is only 14%
(Lugthart et al., 2010). However, animal models with RUNX1-
ETO and RUNX1-EVI1 expression do show similarities. Mice
carrying RUNX1-EVI1 knocked into the RUNX1 locus display a
phenotype similar to the RUNX1-ETO knockin (Maki et al.,
2005; Okuda et al., 1998; Yergeau et al., 1997), as they die at
embryonic day 13.5 (E13.5) with a failure of adult hematopoiesis.
RUNX1-ETO and RUNX1-EVI1 also both require additional sec-
ondary mutations before they can cause AML in mice (Cuenco
et al., 2000; Cuenco and Ren, 2001; Yuan et al., 2001), but
RUNX1-EVI1 promotes a more aggressive leukemia with a
reduced latency (Cuenco et al., 2000; Maki et al., 2006; Schessl
et al., 2005; Schwieger et al., 2002). The molecular mechanisms
underlying these similarities and differences in tumor pathology
and clinical response are unclear. To address these issues, we
compared the gene expression profiles as well as the chromatin
landscape and transcription factor occupancy patterns of pa-
tients carrying the t(8;21) and t(3;21) translocations using global
DNase I hypersensitive site (DHS) mapping, digital DNase I
footprinting, and chromatin immunoprecipitation sequencing
(ChIP-seq). These studies revealed that RUNX1-ETO and
RUNX1-EVI1 associate with distinct subsets of regulatory ele-
ments that bind different classes of transcription factors and
deregulate different sets of genes. As previously observed for
RUNX1-ETO, depletion of RUNX1-EVI1 in t(3;21) cells initiates
myeloid differentiation, which is linked to the upregulation of
genes known to be vital for myeloid differentiation. Importantly,
initiation of differentiation in either type of AML requires the pres-
ence of the master regulator of terminal myeloid differentiation,
C/EBPa. Hence, despite having the same DNA-binding domain,
our data show that the two different RUNX1 fusion proteins
maintain the block in differentiation via unique gene regulatory
networks.
RESULTS
t(3;21) and t(8;21) AML Display Different Epigenetic
Landscapes and Gene Expression Profiles
In order to obtain a first indication of the similarities and differ-
ences in the cistromes regulating gene expression patterns in
t(8;21) and t(3;21) AML we mapped the accessible chromatin
landscape by identifying all DHSs in purified CD34+ leukemic
blast cells of two t(3;21) and two t(8;21) AML patients, two sets
of normal CD34+ progenitor cells purified asmobilized peripheral
blood stem cells (PBSCs) fromperipheral blood, and a t(3;21) cell
line derived from a CML patient in blast crisis (SKH-1; Mitani
et al., 1994)). We performed DNase I sequencing (DNase-seq)
to identify all DHSs within chromatin as described previously
(Ptasinska et al., 2012), and analyzed gene expression profiles
using RNA sequencing (RNA-seq). These comparisons uncov-
ered profound differences in gene expression profiles and DHS
patterns between t(8;21) and t(3;21) AML, in particular with
HOXA-associated genes such as HOXA9 and its partner gene,
MEIS1, which are highly expressed in t(3;21) malignancies, but
not in t(8;21) AML (Figures 1B, S1A, and S1B). The SKH-1 cell
line proved to be a surprisingly good model of primary t(3;21),
as on average 90% of its DHSs overlapped with each of the
two primary AMLs (Figures S1B, S1D, and S1E), despite the1656 Cell Reports 19, 1654–1668, May 23, 2017fact that all three cell types have a very different mutational back-
ground (Table S2). Correlation clustering analyses showed that
DHS and gene expression profiles of t(3;21) and t(8;21) patients
clustered separately as two distinct groups (Figures 1C and 1D)
and showed differential gene expression and DHS patterns (Fig-
ures 1E, 1F, and S1D–S1F). Interestingly, for both DNase-seq
and RNA-seq data, t(3;21) cells clustered closer to normal
CD34+ cells (PBSCs) than t(8;21) cells (Figures 1 C and 1D), sug-
gesting a status close to early progenitor and stem cells for this
type of AML. Furthermore, although RUNX, ETS, AP-1, and
CTCF motifs were shared between the DNA motifs present
within distal DHSs specific for the two patient classes, t(3;21) pa-
tients exhibited a specific enrichment for GATA motifs, whereas
DHSs specific for t(8;21) were enriched inmotifs for CEBP and E-
box-binding factors, as observed previously (Figure 1G) (Ptasin-
ska et al., 2014). In contrast, 90% of DHSs that are common to
both t(3;21) and t(8;21) cells were also shared with normal
CD34+ PBSCs. Consistent with this finding, DHSs common to
both types of AML regulate housekeeping functions (Figure S1C,
right panel).
RUNX1-ETO and RUNX1-EVI1 Are Recruited to an
Overlapping but Distinct Set of Binding Sites
The differential enrichment for GATA, CEBP, and E-box motifs
prompted us to examine whether the binding patterns of
RUNX1-ETO, RUNX1-EVI1, and RUNX1 differ between patient
groups or whether the shared RHD DNA-binding domain would
lead to similar binding pattern. This question is of significant in-
terest, because RUNX1 and RUNX1-ETO have only one DNA-
binding domain, whereas RUNX1-EVI1 has two additional poten-
tial DNA-binding domains derived from EVI1 (the zinc-finger do-
mains; Figure 1A), which can contribute additional DNA speci-
ficity. It has been previously shown by in vitro studies that EVI1
binds to the GATA-like sequence GA(C/T)AAGA(T/C)AAGATAA
(Delwel et al., 1993) and TGACAAGATAA (Perkins et al., 1991),
which resemble one of the t(3;21)-specific motifs (Figure 1G).
To investigate the in vivo specificity of the fusion proteins
compared to RUNX1, we first generated RUNX1 and RUNX1-
EVI1 ChIP-seq data from SKH-1 t(3;21) cells. We then compared
these data with previously published RUNX1-ETO and RUNX1
ChIP data from the t(8;21) Kasumi-1 cell line (Ptasinska et al.,
2012), as well as previously published RUNX1-binding data
from primary CD34+ cells (Cauchy et al., 2015). Both t(8;21)
and t(3;21) AML co-express their respective fusion proteins
together with wild-type RUNX1, but no expression of either
EVI1 (Figure S2A) or ETO was detected, as reported previously
(Mitani et al., 1994; Ptasinska et al., 2014). ETO and EVI1 anti-
bodies therefore detected the fusion proteins, whereas the
C-terminal RUNX1 antibody detected wild-type RUNX1 (Fig-
ure S2A, red).
A variety of tools were used in combination to analyze the ChIP
datasets to demonstrate that despite similar total numbers of
binding sites and genomic distribution, the two fusion proteins
and RUNX1 each bind to overlapping but largely distinct sets
of binding sites (Figures 2A–2D, S2C, S2G, and S3A). In Figures
2E and S2H, we ranked the RUNX1-ETO and the RUNX1-EVI1
or the respective RUNX1ChIP peaks according to fold difference
along the same genomic coordinates (Figures 2E, S2G, and S2H)
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Figure 2. RUNX1-ETO and RUNX1-EVI1 Bind to Different Sites in Each Type of AML
(A) UCSC genome browser screen shot of aligned reads atGATA2 andMEIS1 from ChIP-seq experiments showing binding of RUNX1 (C-terminal antibody) and
RUNX1-EVI1 from t(3;21) SKH-1 cells, RUNX1 and RUNX1-ETO from t(8;21) Kasumi-1 cells, and RUNX1 from normal CD34+ PBSCs. The boxed element in-
dicates the GATA2 enhancer.
(B) Matrix-based depiction of the correlation between ChIP-seq experiments followed by hierarchical clustering.
(C) Venn diagram of peak overlap between ChIP-seq for RUNX1-EVI1 in t(3;21) SKH-1 versus RUNX1-ETO in t(8;21) Kasumi-1. Tables depict de novo motif
analyses of distal sites bound uniquely by each fusion protein. Gray highlights motifs found uniquely in either RUNX1-EVI1- or RUNX1-ETO-bound sites.
(D) Motif enrichment analysis in RUNX1-ETO and RUNX1-EVI1 shared peaks.
(E) RUNX1-EVI1 ChIP peaks were ranked according to tag count, and RUNX1-ETO peaks were plotted alongside, together with motifs for the indicated tran-
scription factors.
See also Figure S2.and then plotted the motifs, again along the same coordinates.
These analyses show unequivocally that the two fusion proteins
as well as RUNX1 show a distinct binding pattern in each cell
type and that GATA motifs partition with RUNX1-EVI1, whereas
E-box and C/EBP motifs partition with RUNX1-ETO. The sameholds true for RUNX1 binding patterns (Figure S2H). Here, we
also plotted our previously reported RUNX1-binding peaks
from normal CD34+ cells alongside (Ptasinska et al., 2014), sup-
porting the idea that the cistrome of t(3;21) cells is related to that
of CD34+ cells. At important myeloid regulator genes, such asCell Reports 19, 1654–1668, May 23, 2017 1657
the CSF-1 receptor gene (CSF1R) and the PU.1 gene (SPI1),
the two fusion proteins target the same regulatory elements
(Figures 3A and S3B) (Himes et al., 2001; Li et al., 2001). At
many other sites the fusion protein binding sites co-localize spe-
cifically with alternate sets of other binding motifs (Figure 2C),
such as GATA motifs in t(3;21) and C/EBP and E-Box sites in
t(8;21). We did not detect the longer GATA-like motifs in the
RUNX1-EVI1 ChIP-seq peaks identified in the in vitro studies
(Figure S2E).
ChIP experiments in t(8;21) cells have shown that RUNX1-ETO
co-associates with a number of hematopoietic regulators such
as the E-box-binding protein HEB; the ETS factors ERG, FLI1,
and PU.1; and the LMO2/LDB1 complex (Martens et al., 2012;
Ptasinska et al., 2014; Sun et al., 2013). To test whether the
GATA motifs in RUNX1-EVI1 peaks were bound by GATA fac-
tors, we examined the expression of GATA-family members in
t(3;21) and t(8;21) patients and found that GATA2, but not
GATA1, was expressed at a higher level in t(3;21) than in
t(8;21) (Figure S3C). Other GATA factors were not expressed at
all (Table S1). ChIP experiments demonstrated that RUNX1-
EVI1, RUNX1, and GATA2 co-associated within a large popula-
tion of sequences (Figures 3A, 3B, and S3D), whichwere charac-
terized by ETS, RUNX, AP-1, and GATA motifs (Figures 3C and
S3E). To identify other enriched motifs at the binding sites of
RUNX1 and the two fusion proteins, we performed a more
refined analysis examining the enrichment of multiple motifs at
binding sites specific for each factor (see analysis scheme above
Figure 3D) and cell type and then clustered the enrichment p-
values (Figure 3D). Such an analysis highlights whether a set of
motifs shows a higher enrichment in one cell type as compared
to another, indicating the binding of different transcription fac-
tors around specific binding sites for each fusion protein and
highlighting the relative importance of a transcription factor fam-
ily in each cell type. For t(8;21) cells, this analysis showed that
RUNX1 and RUNX1-ETO sites cluster separately with a strong
enrichment of RUNX, C/EBP, and GFI1B motifs for both
RUNX1-ETO and RUNX1 peaks (boxed in blue), a selective
enrichment of E-box motifs for RUNX1-ETO peaks, and a spe-
cific enrichment for ETS family motifs for RUNX1 peaks. In
contrast, RUNX1-EVI1 and RUNX1 peaks clustered together in
t(3;21), with a strongly enriched motif signature for GATA,
STAT, HOXA9, and ETS motifs (boxed in green).
To validate our ChIP data in primary cells, we performed digital
DNase I footprinting and identified regions protected from
nuclease digestion indicative of transcription factor binding us-
ing the Wellington algorithm (Piper et al., 2013). We then filtered
footprints against our cell line ChIP data for RUNX1 (in t(8;21) and
t(3;21)), RUNX1-EVI1, and RUNX1-ETO. Finally, we performed a
bootstrapping analysis, which highlights the significance of
occupied motif co-clustering within windows of 50 bp, and
plotted enriched motifs in a co-clustering matrix (Figures 3E,
3F, S3F, and S3G). These analyses showed that RUNX1-EVI1-
binding sites clustered with occupied PU.1/ERG (ETS), AP-1,
and GATA motifs, suggesting that they may exist as a complex.
This is in line with the fact that EVI1 has been shown to directly
interact with the AP-1 family member FOS in several cell lines
(Bard-Chapeau et al., 2012) and to co-localize with AP-1 motifs
(Glass et al., 2013). In contrast, RUNX1-bound sites in t(3;21)1658 Cell Reports 19, 1654–1668, May 23, 2017only co-localized with occupied ERG (ETS) motifs in each cell
type. However, the picture for RUNX1-ETO binding was
different. Occupied RUNX1-ETO-bound sites clustered together
with RUNX, ERG, and E-box motifs (Figure 3D), highlighting the
nature of the RUNX1-ETO complex.
Survival of t(3;21) Cells Depends on the Continuous
Expression of GATA2, but Not RUNX1
Our binding data suggested that RUNX1-EVI1 and RUNX1-ETO
associate with different transcription factor complexes. Further-
more, such differential binding is also found with the wild-type
RUNX1 protein expressed from the non-translocated allele in
each AML type, indicating that RUNX1 fulfills different roles in
programming the chromatin landscape in each cellular context.
It was previously shown that the survival of t(8;21) cells is depen-
dent on the expression of wild-type RUNX1, whereby RUNX1
regulated a complementary set of genes balancing the effects
of RUNX1-ETO (Ben-Ami et al., 2013). We therefore tested
whether this was also true for t(3;21) cells. To this end, we treated
Kasumi-1 and SKH-1 cells with small interfering RNAs (siRNAs)
specific for RUNX1 as well as control siRNAs andmeasured their
survival using staining for the apoptosis marker Annexin V and
propidium iodide (PI), which indicates dead cells. Figures 3G,
3H (left), and S3H–S3J demonstrate that after 5 days of knock-
down, t(8;21) cells showed in increased cell death as compared
to control cells, while SKH-1 cells showed no difference and thus
do not require wild-type RUNX1.
Previous studies have shown that themembers of the RUNX1-
ETO complex (namely LMO2 and ERG) are required for the leu-
kemogenicity of RUNX1-ETO and their survival (Sun et al., 2013).
To gain first insights into whether GATA2 was preferentially
required for the survival of t(3;21) cells, we depleted GATA2 in
both t(3;21) and t(8;21) cells by siRNA treatment (Figures 3G
and 3H, right, and Figures S3H–S3J) and measured their survival
using staining for Annexin V and PI. These experiments show a
strong increase in the number of apoptotic and dead cells in
t(3;21) cells, but not in t(8;21) cells, indicating that GATA2 plays
a more important role in the survival of t(3;21) cells than in
t(8;21) cells.
Taken together, our data demonstrate that despite sharing the
same DNA-binding domain, the two fusion proteins predomi-
nantly bind to different genomic sites, co-bindwith different part-
ners, and operate within a different chromatin landscape. More-
over, the transcriptional networks regulating the survival of both
types of AML depend on different non-mutated transcription fac-
tors, with t(8;21) cell depending on RUNX1 and t(3;21) cell being
dependent on GATA2.
RUNX1-EVI1 Is Required to Maintain the
Undifferentiated Phenotype and Survival of t(3;21) AML
The t(8;21) translocation is a driver mutation (Wiemels et al.,
2002), and RUNX1-ETO expression is required to maintain the
leukemic phenotype in t(8;21) AML (Dunne et al., 2006). In
contrast, RUNX1-EVI1 is a secondary mutation found in second-
ary AML and in CML in blast crisis (Nukina et al., 2014; Paquette
et al., 2011; Rubin et al., 1987, 1990).We therefore used an siRNA
knockdown approach to investigate whether RUNX1- was also
required to maintain the full leukemic potential of t(3;21) cells.
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Figure 3. RUNX1 Fusion Proteins Form Part of a Gene Regulatory Network Unique to Each Leukemia
(A) UCSC genome browser screen shot of Spi1 showing ChIP-seq data of RUNX1 and RUNX1-EVI1 from t(3;21) SKH-1 cells, RUNX1 and RUNX1-ETO from
t(8;21) Kasumi-1 cells, and RUNX1 from normal CD34+ PBSCs.
(B) GATA2, RUNX1-EVI1, and RUNX1 ChIP-seq in t(3;21) SKH-1 cells. Venn diagram depicting the overlap betweenGATA2, RUNX1-EVI1, and RUNX1 peaks and
the numbers of peaks in each group. White: overlap of GATA2- and RUNX1-EVI1-bound sites; purple: overlap of GATA2 and RUNX1 bound sites; yellow: overlap
of RUNX1- and RUNX1-EVI1-bound sites; gray: number of sites bound by all three transcription factors.
(C) Transcription-factor-binding motifs enriched in the shared peaks from (B).
(D) Hierarchical clustering of enriched motifs discovered in a pairwise comparison between RUNX1 and RUNX1 fusion ChIP-seq peaks between t(3;21) and t(8;21)
cells identifying unique peaks for each type of AML. Enrichment score was calculated by the level of motif enrichment in the unique peaks as compared to union of
peaks in the pair of experiments. The heatmap depicts the degree of motif enrichment. Two specific sets of enrichedmotifs unique to each ChIP seq experiment are
highlighted: theblueboxhighlights specifically enrichedmotifs inRUNX1-boundsites, thegreenboxhighlightsenrichedmotifs specific for t(3;21)but not otherpeaks.
(E and F) Bootstrapping analysis of footprinted motifs at RUNX1-EVI1- or RUNX1-ETO-binding sites in patient cells. RUNX1-EVI1-binding sites from the t(3;21)
SKH-1 cell line (E) and RUNX1-ETO-binding sites from the t(8;21) Kasumi-1 cell line (F) mapped onto footprints generated from DNase I data of either t(3;21)
(legend continued on next page)
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We targeted the siRNA to the junction between RUNX1 and EVI1
to specifically deplete RUNX1-EVI1, but not RUNX1 (Figures S2A
and S4A). We transfected SKH-1 with this siRNA and control
siRNA, in parallel with control K562 cells, over a period of 2–
14 days (Figure 4A). Flow cytometry revealed that SKH-1 cells
transfected with RUNX1-EVI1 siRNA, but not control RNA,
decreased the expression of the progenitor cell marker CD34
(Figures 4B and 4C). SKH-1 cells treated with siRNA, but not
K562 cells, showed a diminished growth rate (Figure 4D) and
started to undergo apoptosis (Figures S4B and S4C), indicating
that the fusion protein is required for their survival. The analysis
of RNA-seqdata revealed significant changes in gene expression
after knockdown (Figures 4E, 4F, and S4E; Table S1) with genes
being progressively up- and downregulated. qPCR analyses
confirmed that genes downregulated by siRNA included stem
cell genes such asGATA2 (Figures 5A–5C), whereas upregulated
genes included myeloid differentiation markers such as MPO,
CSF1R, CTSG, and CEBPA (Figures 5E–5H and S4F). The
expression of CEBPB was unaffected (Figure 5D). Gene set
enrichment analysis (GSEA) showed that the cells downregulated
a stem cell program after knockdown of RUNX1-EVI1 (Figures
S5A and S5B). Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway analysis for RUNX1-EVI1 target genes downre-
gulated after RUNX1-EVI1 knockdown highlighted multiple
signaling genes, such as PIM1, DUSP1, DUSP6, JAK1, and
JAK3 (Figure 5I). A parallel analysis of upregulated genes identi-
fied CEBPA, KIT, and MPO (Figure S5F). A more refined picture
was also seen when we analyzed downregulated core genes
bound by RUNX1-EVI1, RUNX1, and GATA2 (Figure 5J). This
analysis again identified genes encoding for factors important
for stem cell function such as ERG, WT1, and MEIS1.
C/EBPa Is Required for the Response of t(3;21) Cells
to RUNX1-EVI1 Knockdown
To identify factors that are involved in driving the differentiation
of t(3;21) cells after RUNX1-EVI1 knockdown, we examined the
changes in the epigenetic landscape of t(3;21) SKH-1 cells by
mapping DHSs in cells treated with a control siRNA or after
10 days of knockdown with a RUNX1-EVI1-specific siRNA (Fig-
ure S5C). Examples of these data are depicted in the genome
browser screenshots shown in Figures 6A, 6B, and S6A. We
then ranked our DHS data according fold difference in
sequence tag count (Figure S5D). This analysis revealed three
groups of elements: a small group of peaks (group 1) unique
for control cells, a large number of shared peaks (group 2),
and 2,510 peaks that only appeared after knockdown (group
3). A de novo analysis of DNA motifs in these groups revealed
that C/EBP motifs were specifically enriched in the DHSs
gained after knockdown (Figure S5E). These results were
concordant with the downregulation of GATA2 and the upregu-
lation of CEBPA expression after RUNX1-EVI1 knockdownpatient 2 or t(8;21) patient 1, respectively. The heatmap shows the significance of
AML as compared to sampling by chance alone.
(G and H) Percentage of Annexin-V-positive cells after 5 days of treatment w
respectively, in Kasumi-1 cells (G) and SKH1 cells (H). Each experiment was done
**p < 0.01 by unpaired t test. n.s. not significant.
See also Figure S3.
1660 Cell Reports 19, 1654–1668, May 23, 2017(Figures 5A and 5H). To examine whether these changes in
gene expression and motif composition were reflected in
changes of binding of the respective factors, we measured
the binding of RUNX1, GATA2, and C/EBPa before and after
10 days of RUNX1-EVI1 knockdown (Figures 6A, 6B, and S6A
show screenshots). These experiments show that RUNX1-
EVI1 knockdown did not influence the overall global genomic
distribution of binding sites for these factors (Figure 6C) and
did not influence the binding levels of RUNX1, although there
was both a decrease in binding at some sites and increases
in binding at others (Figures 6E and S6B). GATA2 binding
decreased slightly overall and some binding sites were lost
(Figures 6D and S6C), which can be explained by the lower
expression of the GATA2 gene (Figure 5A). These findings
also demonstrated that GATA2 binding was not categorically
dependent on the presence of RUNX1-EVI1. However,
C/EBPa binding levels were increased (Figure 6D and 6E) with
a number of new binding sites (Figure S6D). An alignment of
DNA motifs and the DHS peaks confirmed that following
RUNX1-EVI1 knockdown, C/EBP motif containing DHSs
increased (group 3) in parallel with a depletion of GATA motif
containing DHSs (group 1)(Figure 6F). In contrast, ERG,
RUNX, and AP-1 motifs were relatively evenly distributed
(Figure 6F). CEBPA upregulation is likely to be caused by the
reduction of binding of RUNX1-EVI1 after knockdown with a
concomitant increase of the binding of RUNX1 and C/EBPa it-
self to the CEBPA locus (Figure S6E).
We next examined whether upregulation of C/EBPa was
required for the response to oncogene depletion. To this end,
we transduced SKH-1 cells with a lentiviral vector expressing a
dominant-negative CEBP peptide (DNCEBP) to block C/EBPa
binding (and that of all other C/EBP factors) during knockdown
RUNX1-EVI1 by siRNA. The DNCEBP peptide dimerizes with
CEBP transcription factors and prevents binding to DNA (Krylov
et al., 1995). Expression of the FLAG-epitope-tagged DNCEBP
peptide was confirmed by western blotting (Figure 7A). We
then treated control and DNCEBP SKH-1 cell lines with
RUNX1-EVI1 siRNA (Figures S7A and S7B). While RUNX1-EVI1
knockdown decreased CD34 expression and proliferation, co-
expression of the DNCEBP peptide rescued the leukemic
phenotype (Figures 7B, 7C, and S7C). Similarly, DNCEBP-ex-
pressing cells maintained high expression of HOXA9 after
RUNX1-EVI1 knockdown, slowed the decrease of the key stem
cell renewal genes GATA2 and MEIS1, and blocked increased
expression of the markers of myeloid differentiation CTSG,
MPO, and CSF1R (Figures 7D, 7E, and S7B). ChIP experiments
confirmed reduced C/EBPa binding at the corresponding
loci after DNCEBP expression (Figure 7F). Another interesting
finding was that the expression of DNCEBP also reduced the
increase in RUNX1 binding at a set of known C/EBP and
RUNX1 target genes (Figures 7F and 7G) with a concomitantco-localizing footprinted motifs at RUNX1 fusion protein-binding sites for each
ith a control siRNA (siMM) or with siRNAs specific for RUNX1 and GATA2,
at least in triplicate as indicated, and error bars represent SEM. *p < 0.05 and
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Figure 4. Knockdown of RUNX1-EVI1 Results in Loss of the Stem Cell Gene Program
(A) Experimental scheme for the siRNA transfection.
(B and C) RUNX1-EVI1 siRNA treatment in SKH-1 cells results in reduction in CD34 surface expression. SKH-1 cells after 14 days of either RUNX1-EVI1 or control
siRNA transfection were stained with CD34-PE and CD117-APC. (B) Percentage of CD34+CD117+ cells. (C) Representative flow cytometry plot. Mean of six
independent experiments is shown. Error bars represent SEM. *p < 0.05 by paired t test.
(D) Growth rates of SKH-1 (dashed lines) and K562 cells (solid lines) treated with RUNX1-EVI1 siRNA relative to treatment with control siRNA. The graph shows
mean and SEM values from at least three independent experiments.
(E) Hierarchical clustering of gene expression changes as determined by RNA-seq at different time points of treatment. Unsupervised clustering of expression
values of genes changing expression 1.5-fold after RUNX1-EVI1 siRNA transfection as compared to control siRNA. Average of two independent replicates. The
heatmap color is related to the degree of differential expression (fold change [FC]) between RUNX1-EVI1 siRNA and control siRNA treatment.
(F) Percentage and number, respectively (on top of bars), of differentially expressed genes as measured by RNA-seq that are RUNX1-EVI1 ChIP-seq targets.
Differentially expressed genes are those with an at least 1.5-fold change in gene expression between RUNX1-EVI1 siRNA as compared to control siRNA
treatment.
See also Figure S4.reduction in DNase I accessibility at genes strongly activated by
RUNX1-EVI1 knockdown, such asMPO orCTSG, indicating that
here, the cooperation of C/EBPa and RUNX1 is required for acti-
vation (Figures 7H and S7D).
Taken together, as summarized in Figure 7I, our study high-
lights how specific oncogenic transcription factors differentially
program the epigenetic landscape in two types of AML with
RUNX1 translocations but share the feature that they are depen-dent on the expression of the fusion protein and the suppression
of C/EBPa to inhibit differentiation.
DISCUSSION
The study presented here used global analyses to investigate dif-
ferences and similarities between two types of CBF AML: the
t(8;21) expressing RUNX1-ETO and the t(3;21) expressingCell Reports 19, 1654–1668, May 23, 2017 1661
05
10
15
20
25
30
2 4 7 10 14 0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
2 4 7 10 14
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
2 4 7 10 14R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n 
le
ve
l GATA2
CEBPAMPO
Control siRNA RUNX1-EVI1 siRNA
Days
Days
Days
A B
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2 4 7 10 14 0.0
0.5
1.0
1.5
2.0
2.5
3.0
2 4 7 10 14
D
E
Days Days
CTSGCSF1R
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2 4 7 10 14 0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2 4 7 10 14
Down regulated RUNX1-EVI1 target genes 
responding to RUNX1-EVI1 knock-down
MEIS1 HOXA9
Days Days
C
F G
Down regulated GATA2, RUNX1 and RUNX1-EVI1 bound genes 
responding to RUNX1-EVI1 knock-down
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2 4 7 10 14
CEBPB
Days
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n 
le
ve
l
H
n.s. ***0.06 *
n.s. *n.s. **n.s.
n.s. **n.s. *0.07
n.s. **** ***
n.s. **** ****
0.09 **** *** n.s. *** ***
n.s. n.s. *n.s. n.s.
I J
TNFRSF10DIL10RA
JAK1 JAK3
IL1B
cGMP-PKG
signaling pathway 
VASP
GNA12
Platelet activation
GP1BB
GP9
LYN
GUCY1A3
Long-term
depression
BIN1
F2R
Fc gamma 
R-mediated
phagocytosis
JUPGSN NFKBIZ
TBXAS1
NFATC2
MEF2C
GNAI1
DUSP6FGFR2
PRKD2
WT1
Rap1 signaling 
pathway
Transcriptional
misregulation in 
cancer
RAPGEF2
PIK3CG
RALB Toxoplasmosis
CIITA
ERG
Measles
MEIS1TAB2
IL10RA
JAK1
CIITA
Acute myeloid 
leukemia PIM1
TuberculosisJUP
ZEB1CD34
Hematopoietic
cell lineage 
MEIS1GP9
WT1
TBXAS1
NFKBIZ
Platelet activation DUSP6
GP1BB Transcriptional
misregulation in 
cancerGUCY1A3
MEF2CF2R
DUSP1
ERG
FERMT3
GNA12
NFATC2
Osteoclast
differentiation
MAPK signaling 
pathway
Pathways in 
cancer
SUFU
GNAI1
GSN
Jak-STAT
signaling pathway 
PIK3C2B
Inositol
phosphate
metabolism
JAK3Viral
carcinogenesis
SOCS2
SYNJ2
HK1 Type II diabetes 
mellitus
cGMP-PKG
signaling pathway 
Fc gamma 
R-mediated
phagocytosis
RALB
BIN1
Rap1 signaling 
pathway
PRKD2
VASP
INPP4B
NOD-like receptor 
signaling pathway 
IL1B
CASP10
TAB2
NLRP1
TGFB1
DAPK1
Toxoplasmosis
LYN
HDAC7
PIK3CG
GNB5
Figure 5. Knockdown of RUNX1-EVI1 Results in Loss of the Expression of Stem Cell Genes and the Upregulation of Myeloid Genes
(A–H) RT-PCR analysis of mRNA levels of the indicated genes relative to GAPDH and normalized to untreated cells in SKH-1 cells after RUNX1-EVI1 siRNA as
compared to control siRNA transfection. GATA2 (A),MEIS1 (B), HOXA9 (C), CEBPB (D), CSF1R (E), CTSG (F), MPO (G), and CEBPA (H). The graph shows mean
and SEM of four independent experiments. n.s., not significant; *p < 0.05; **p < 0.01 (unpaired t test). See also Table S1.
(I) KEGG pathways highlighting genes and pathways that are upregulated after RUNX1-EVI1 knockdown.
(J) KEGG pathways highlighting pathways associated with genes with shared binding of GATA2, RUNX1, and RUNX1-EVI1 that are upregulated after RUNX1-
EVI1 knockdown.
See also Figure S5.RUNX1-EVI1, which both carry the same RUNX1 DNA-binding
domain. Our DHS mapping, digital footprinting experiments,
and ChIP assays of patient cells and appropriate patient-derived
model cell lines unequivocally determined how (1) the epigenetic
and transcriptional profiles of the two types of AML differ and (2)
show that the RUNT DNA-binding domain of each fusion protein
is not the sole determining factor for the selection of fusion pro-
tein-binding sites in the genome. Moreover, each type of AML1662 Cell Reports 19, 1654–1668, May 23, 2017displays a unique, stable transcriptional network that is depen-
dent on the presence of each fusion protein but requires a
different set of associated transcription factors.
t(3;21) and t(8;21) AMLDisplay Alternate Transcriptional
Networks
The RUNX1-ETO and RUNX1-EVI1 fusion proteins are both un-
able to cause leukemia in mice on their own (Cuenco et al.,
A B
C
E F
D
Figure 6. RUNX1-EVI1 Knockdown Results in Genome-wide Reprogramming of the Epigenome
(A and B) UCSC genome browser screen shots showing aligned reads atMPO (A) and MEIS1 (B) depicting DNase-seq and RUNX1, RUNX1-EVI1, GATA2, and
C/EBPa ChIP-seq data from SKH-1 after either control siRNA or RUNX1-EVI1 siRNA treatment.
(C) Genomic distribution of the indicated factors after transfection with either control or RUNX1-EVI1 siRNA.
(D) Average profiles of RUNX1-EVI1, RUNX1, C/EBPa, and GATA2 ChIP-seq reads centered on RUNX1-EVI1 peaks within a 4-kb window after transfection with
either control or RUNX1-EVI1 siRNA.
(E) Profiles of the DNase-seq and ChIP-seq tag density for the indicated factors in ±4-kb windows centered on DHS for SKH-1 treated with either control or
RUNX1-EVI1 siRNA. All peaks were ranked according to the fold change in DNase-seq tag counts between control siRNA and RUNX1-EVI1 siRNA-treated SKH-1
cells.
(F) Densities of the indicated motifs underlying the same coordinates plotted within ±1-kb windows around the DHS marked with a blue arrow.
See also Figure S6.2000; Okuda et al., 1998), and they show a different history of
tumor development in humans. The t(8;21) translocation is a pri-
marymutation that hits an early stem cell (Miyamoto et al., 2000),
whereas t(3;21) is often found in CML patients after blast crisis,
indicating that during tumor initiation, the two fusion proteins
encounter a dramatically different chromatin landscape that
dictates where they can bind. Previous studies from our labora-
tory that used an inducible version of RUNX1-ETO expressed in
murine myeloid precursor cells demonstrated that the inductionof the fusion protein leads to a rapid downregulation of myeloid
genes such as Spi1(PU.1) and Cebpa and a concomitant in-
crease in the expression of stem cell genes such as Gata2 and
Erg, indicating extensive feed-forward loops driving myelopoie-
sis (Regha et al., 2015). It is likely that the same holds true for
RUNX1-EVI1, but a different differentiation stage or previous
transformation event may be required for the establishment of
a stable transformed transcriptional network incorporating the
expression of this powerful oncoprotein.Cell Reports 19, 1654–1668, May 23, 2017 1663
The unique transcriptional network maintained by RUNX1-
EVI1 explains the difference in clinical outcomes of t(3;21) as
compared to t(8;21) AML. RUNX1-EVI1 appears to directly
regulate a stem cell program establishing an immature pheno-
type associated with treatment resistance, (Eppert et al., 2011),
expressing genes (MSI2 and ZEB1) regulating leukemia aggres-
siveness (Ito et al., 2010; Stavropoulou et al., 2016). Further-
more, HOXA9 and MEIS1 are both expressed in t(3;21), but
not in t(8;21), AML. HOXA9 expression is associated with
poor prognosis (Andreeff et al., 2008; Golub et al., 1999), and
is linked to a number of mutational subtypes, including mixed
lineage leukemia (MLL) and NUP98 translocations (Collins and
Hess, 2016). MEIS1 expression is also associated with poor
prognosis as part of a gene expression pattern seen in HSCs
and LSCs (Eppert et al., 2011). HOXA9 and MEIS1 are often
co-expressed in AML (Lawrence et al., 1999) and Hoxa9 re-
quires the co-expression of Meis1 to transform murine bone
marrow progenitor cells (Kroon et al., 1998). This cooperativity
can be explained by the identification of a large number of cis-
regulatory elements that are co-bound by both Hoxa9 and
Meis1 (Huang et al., 2012).
The different gene regulatory networks maintaining the two
types of AML involve alternate sets of transcription factors,
and they differentially program the chromatin landscape, thus
impacting where the fusion proteins bind. Our data show that
RUNX1-ETO-binding sites are enriched for occupied ETS/
RUNX/E-box motifs, reflecting the structure of the RUNX1-
ETO complex, with the ETS factors ERG and FLI1 in the com-
plex being required for leukemia maintenance and leukemo-
genesis (Martens et al., 2012; Sun et al., 2013). The expression
of ERG in AML is generally associated with poor prognosis
(Diffner et al., 2013). In contrast, RUNX1-EVI1 co-localizes
with bound GATA2 and occupied AP-1 motifs, suggesting as-
sociation with a different complex. Our data indeed show that
high-level GATA2 expression is required for the survival of
SKH-1 cells, but not t(8;21) cells, whereas RUNX1 regulates a
complementary set of genes and is required for the survival
of t(8;21) cells (Ben-Ami et al., 2013), but not SKH-1 cells
(this study). High expression of GATA2 is indeed associated
with poor prognosis in pediatric AML (Luesink et al., 2012),
which may contribute to the fact that the t(3;21) is more aggres-
sive than t(8;21). How each CBF fusion protein complex pro-
grams the DHS landscape, causing differential expression of
members of the each complex, is exemplified by the regulation
of GATA2. GATA2 expression is higher in t(3;21) cells than in
t(8;21) cells, which can be explained by a differential activity
of its cis-regulatory elements. Our data show that a distal
GATA2 enhancer, known to upregulate GATA2 expression
(Gro¨schel et al., 2014), is accessible and bound by RUNX1 in
normal CD34+ cells, and by RUNX1 and RUNX1-ETO in
t(8;21) patient cells, but neither RUNX1 nor RUNX1-EVI1 binds
to this element in t(3;21) cells.
In summary, RUNX1 and both fusion protein complexes bind
to AML-type specific cis-regulatory modules, which through
auto-regulation of genes encoding complex members initiate
the formation of stable gene regulatory networks that ultimately
define the behavior of each type of AML (Pimanda and Go¨ttgens,
2010).1664 Cell Reports 19, 1654–1668, May 23, 2017C/EBPa Is Required for the Differentiation of t(8;21) and
t(3;21) AML Cells after Oncoprotein Knockdown
Despite the differences between t(3;21) and t(8;21) trans-
criptional networks, C/EBPa is downregulated in both types of
AML, suggesting that it is a critical node by which leukemia is
maintained. We show that C/EBPa is directly repressed by
both RUNX1-EVI1 andRUNX1-ETO through binding to a recently
characterized upstream enhancer (Avellino et al., 2016). In both
t(8;21) and t(3;21) cells, knockdown of the CBF fusion protein
leads to upregulation of CEBPA, and our ChIP-seq data directly
show that the binding of C/EBPa is affected by the knockdown of
both fusion proteins. Conversely, in both AML types, the reduc-
tion of C/EBPa-binding activity by either knockdown (Ptasinska
et al., 2014) or expression of a dominant-negative version of
C/EBP (DNCEBP) blocks myelopoiesis and abolishes the
upregulation of genes required for terminal myeloid function
(MPO, CSF1R, and CTSG). This result complements previous
data showing that overexpression of CEBPA can overcome the
RUNX1-EVI1-mediated differentiation block (Tokita et al.,
2007). An interesting finding from our study is that that the block
of C/EBPa binding also abolishes the establishment of specific
DHSs at certain genes and the binding of other transcription
factors, including RUNX1. C/EBPa interacts with SWI/SNF
nucleosome remodeling complexes, and this interaction is
important for the development of adipocytes (Pedersen et al.,
2001). This ability to initiate a global reprogramming of chromatin
structures may be the main driver of C/EBPa-mediated myeloid
differentiation, and current experiments focus on the mecha-
nistic details of how this occurs.
Taken together, our study provides an important paradigm for
studies aimed at understanding how different leukemic fusion
proteins program and interact with the epigenetic landscape in
two related but different types of AML. Our data represent a
resource that will facilitate global mechanistic studies of the
genes, transcription factors, and pathways involved in blocking
myeloid differentiation and emphasize that different types of
AML, despite being a disease of one specific differentiation
pathway, are maintained by highly diverse transcriptional net-
works. Our study therefore highlights the complexities we have
to face in our understanding of AML heterogeneity if we want
to use this knowledge to devise AML-specific therapies.
EXPERIMENTAL PROCEDURES
Purification of Leukemic Cells and Mobilized Peripheral Stem Cells
Cells were purified as described previously (Cauchy et al., 2015), with minor
modifications as outlined in in Supplemental Experimental Procedures.
siRNA-Mediated Depletion
13 107 cells were electroporated using an EPI 3500 (Fischer) at 350 V, 10 ms.
siRNA sequences are listed in the Supplemental Experimental Procedures.
siRNA was used at 200 nM. After electroporation, the cells remained in their
cuvettes for 5 min before being directly added to RPMI-1640 with 10% fetal
calf serum (FCS), supplemented with penicillin/streptomycin and glutamine
at a concentration of 0.5 3 106 cells/mL, returned to an incubator, and kept
at 37C and 5% CO2.
DHS Mapping, ChIP-Seq, and Digital Footprinting
DHS mapping, ChIP-seq, and digital footprinting using the Wellington algo-
rithm (Piper et al., 2013) was performed as described previously (Cauchy
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et al., 2015; Ptasinska et al., 2014), with minor modifications as outlined in in
Supplemental Experimental Procedures. Details of antibodies and primers
for qPCR are listed in Tables S3 and S4. Sequencing read data and list of
peak numbers can be found in Table S3.
Data Analysis
Details of data analyses can be found in Supplemental Experimental
Procedures.
Patient Samples
All human tissue was obtained with the required ethical approval from the
National Health Service (NHS) National Research Ethics Committee. Detailed
information about patient samples is listed in Table S2.
ACCESSION NUMBERS
The accession number for all t(3;21) next generation sequencing data reported
in this paper is GEO: GSE87286.
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six figures, and four tables and can be found with this article online at http://
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